Helex is extending the frontier of breakthrough gene editing-based therapeutics to meet the significant underserved medical needs of patients with genetic kidney diseases.
Helex is extending the frontier of breakthrough gene editing-based therapeutics to meet the significant underserved medical needs of patients with genetic kidney diseases.
Avoiding unwanted editing in non-target cells and tissues for higher safety of in vivo editing
Comprehensive short term and long-term impact estimation of editing on the genome and cell functioning
Proprietary target identification, rational gene editing drug design to suit multiple editing nucleases
Reshaping gene editing by leveraging nature’s own operating system-epigenome and the 3-D spatial organization of the genome to develop effective, safe and reliable therapies to provide cures to genetic conditions.
Avoiding unwanted editing in non-target cells and tissues for higher safety of in vivo editing
Comprehensive short term and long-term impact estimation of editing on the genome and cell functioning
Proprietary target identification, rational gene editing drug design to suit multiple editing nucleases